Abstract :
We thank for the interest and comments by Prof. S-M Alavian regarding our article about the prevalence of Hepatitis C Virus in hemodialysis patients. [1]Regarding the use of erythropoietin, we agree that its use has significantly decreased the posttransfusion complications including HCV infection and we agree that this was not mentioned in our study, however, regarding the adherence to universal precautions, we have mentioned in brief that all units included in the study were required to strictly and equivocally adherent to these precautions.
